Hyperuricemia and chronic kidney disease: an enigma yet to be solved

References

• Edwards NL. The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008;75(Suppl. 5):S13–S16
   PubMedGoogle Scholar
• Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis. 2007;50(2):239–247
   PubMed Web of Science ®Google Scholar
• Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis. 2009;53(5):796–803
   PubMed Web of Science ®Google Scholar
• Murea M. Advanced kidney failure and hyperuricemia. Adv Chronic Kidney Dis. 2012;19(6):419–424
   Google Scholar
• Ohno I, Yamaguchi Y, Saikawa H, et al. Sevelamer decreases serum uric acid concentration through adsorption of uric acid in maintenance hemodialysis patients. Intern Med. 2009;48(6):415–420
   Google Scholar
• Singh JA. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 2013;15(2):307
   PubMed Web of Science ®Google Scholar
• Bellomo G. Uric acid and chronic kidney disease: A time to act? World J Nephrol. 2013;2(2):17–25
   Google Scholar
• Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–1106
   PubMed Web of Science ®Google Scholar
• Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002;282(6):F991–F997
   PubMed Web of Science ®Google Scholar
• Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40(3):355–360
   PubMed Web of Science ®Google Scholar
• Kanellis J, Kang DH. Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Semin Nephrol. 2005;25(1):39–42
   PubMed Web of Science ®Google Scholar
• Hsu SP, Pai MF, Peng YS, Chiang CK, Ho TI, Hung KY. Serum uric acid levels show a ‘J-shaped’ association with all-cause mortality in hemodialysis patients. Nephrol Dial Transplant. 2004;19(2):457–462
   PubMed Web of Science ®Google Scholar
• Latif W, Karaboyas A, Tong L, et al. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population. Clin J Am Soc Nephrol. 2011;6(10):2470–2477
   PubMed Web of Science ®Google Scholar
• Domrongkitchaiporn S, Sritara P, Kitiyakara C, et al. Risk factors for development of decreased kidney function in a southeast Asian population: A 12-year cohort study. J Am Soc Nephrol. 2005;16(3):791–799
   Web of Science ®Google Scholar
• Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. J Am Soc Nephrol. 2008;19(6):1204–1211
   PubMed Web of Science ®Google Scholar
• Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol. 2008;19(12):2407–2413
   PubMed Web of Science ®Google Scholar
• Sonoda H, Takase H, Dohi Y, Kimura G. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol. 2011;33(4):352–357
   PubMedGoogle Scholar
• Wang S, Shu Z, Tao Q, Yu C, Zhan S, Li L. Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan. Nephrology (Carlton). 2011;16(8):767–776
   Google Scholar
• Mok Y, Lee SJ, Kim MS, Cui W, Moon YM, Jee SH. Serum uric acid and chronic kidney disease: The Severance cohort study. Nephrol Dial Transplant. 2012;27(5):1831–1835
   Google Scholar
• Kuo CF, Luo SF, See LC, et al. Hyperuricaemia and accelerated reduction in renal function. Scand J Rheumatol. 2011;40(2):116–121
   PubMed Web of Science ®Google Scholar
• Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009;169(4):342–350
   PubMed Web of Science ®Google Scholar
• Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44(4):642–650
   PubMed Web of Science ®Google Scholar
• Iseki K, Iseki C, Kinjo K. Changes in serum uric acid have a reciprocal effect on eGFR change: A 10-year follow-up study of community-based screening in Okinawa, Japan. Hypertens Res. 2013;36(7):650–654
   Google Scholar
• Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis. 2010;56(2):264–272
   PubMed Web of Science ®Google Scholar
• Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000;10(6):403--409
   PubMedGoogle Scholar
• Yen CJ, Chiang CK, Ho LC, et al. Hyperuricemia associated with rapid renal function decline in elderly Taiwanese subjects. J Formos Med Assoc. 2009;108(12):921–928
   Google Scholar
• Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol. 2006;17(5):1444–1452
   Google Scholar
• Shi Y, Chen W, Jalal D, et al. Clinical outcome of hyperuricemia in IgA nephropathy: A retrospective cohort study and randomized controlled trial. Kidney Blood Press Res. 2012;35(3):153–160
   PubMed Web of Science ®Google Scholar
• Yang Z, Liang Y, Xi W, Zhu Y, Li C, Zhong R. Association of serum uric acid with lupus nephritis in systemic lupus erythematosus. Rheumatol Int. 2011;31(6):743–748
   Google Scholar
• Jalal DI, Chonchol M, Chen W, Targher G. Uric acid as a target of therapy in CKD. Am J Kidney Dis. 2013;61(1):134–146
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: Which is chasing which? Nephrol Dial Transplant. 2013;28(9):2221–2228
   PubMed Web of Science ®Google Scholar
• Sturm G, Kollerits B, Neyer U, Ritz E, Kronenberg F. MMKD Study Group. Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. Exp Gerontol. 2008;43(4):347–352
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283(5):F1105–F1110
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Tapia E, Soto V, et al. Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant. 2008;23(4):1179–1185
   PubMed Web of Science ®Google Scholar
• Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269–275
   PubMed Web of Science ®Google Scholar
• Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13(12):2888–2897
   PubMed Web of Science ®Google Scholar
• Omori H, Kawada N, Inoue K, et al. Use of xanthine oxidase inhibitor febuxostat inhibits renal interstitial inflammation and fibrosis in unilateral ureteral obstructive nephropathy. Clin Exp Nephrol. 2012;16(4):549–556
   PubMed Web of Science ®Google Scholar
• Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol. 2007;39(4):1227–1233
   PubMedGoogle Scholar
• Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47(1):51–59
   PubMed Web of Science ®Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol. 2010;5(8):1388–1393
   PubMed Web of Science ®Google Scholar
• Sezer S, Karakan S, Atesagaoglu B, Acar FN. Allopurinol reduces cardiovascular risks and improves renal function in pre-dialysis chronic kidney disease patients with hyperuricemia. Saudi J Kidney Dis Transpl. 2014;25(2):316–320
   Google Scholar
• Sakai Y, Otsuka T, Ohno D, Murasawa T, Sato N, Tsuruoka S. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease. Ren Fail. 2014;36(2):225–231
   Web of Science ®Google Scholar
• Wang H, Wei Y, Kong X, Xu D. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: A meta-analysis. J Ren Nutr. 2013;23(5):389–396
   Google Scholar
• Bose B, Badve SV, Hiremath SS, et al. Effects of uric acid-lowering therapy on renal outcomes: A systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29(2):406–413
   PubMed Web of Science ®Google Scholar
• Mohandas R, Johnson RJ. Uric acid levels increase risk for new-onset kidney disease. J Am Soc Nephrol. 2008;19(12):2251–2253
   Google Scholar
• Gonick HC, Rubini ME, Gleason IO, Sommers SC. The renal lesion in gout. Ann Intern Med. 1965;62:667–674
   Google Scholar
• Bluestone R, Waisman J, Klinenberg JR. Chronic experimental hyperuricemic nephropathy. Lab Invest. 1975;33(3):273–279
   PubMed Web of Science ®Google Scholar
• Waisman J, Mwasi LM, Bluestone R, Klinenberg JR. Acute hyperuricemic nephropathy in rats. An electron microscopic study. Am J Pathol. 1975;81(2):367–378
   Google Scholar
• Zhou Y, Fang L, Jiang L, et al. Uric acid induces renal inflammation via activating tubular NF-κB signaling pathway. PLoS One. 2012;7(6):e39738
   PubMed Web of Science ®Google Scholar
• Ryu ES, Kim MJ, Shin HS, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013;304(5):F471–F480
   PubMed Web of Science ®Google Scholar
• Tarng DC, Lin HY, Shyong ML, Wang JS, Yang WC, Huang TP. Renal function in gout patients. Am J Nephrol. 1995;15(1):31–37
   Google Scholar
• Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore). 1960;39:405–467
   PubMed Web of Science ®Google Scholar
• Nickeleit V, Mihatsch MJ. Uric acid nephropathy and end-stage renal disease – Review of a non-disease. Nephrol Dial Transplant. 1997;12(9):1832–1838
   Google Scholar
• Sowers JR, Whaley-Connell A, Hayden MR. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Med. 2011;1(1):5–12
   Google Scholar
• Sowers JR. Diabetes mellitus and vascular disease. Hypertension. 2013;61(5):943–947
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yamamoto T, Hisatome I, et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol. 2013;375(1-2):89–96
   Google Scholar
• Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008–3011
   PubMed Web of Science ®Google Scholar
• Khitan Z, Kim DH. Fructose: A key factor in the development of metabolic syndrome and hypertension. J Nutr Metab. 2013;2013:682673
   PubMedGoogle Scholar
• Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol. 2009;297(2):F481–F488
   PubMed Web of Science ®Google Scholar
• Kim SM, Choi YW, Seok HY, et al. Reducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathy. Nephron Exp Nephrol. 2012;121(3-4):e109–e121
   Google Scholar
• Hovind P, Rossing P, Tarnow L, Johnson RJ, Parving HH. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study. Diabetes. 2009;58(7):1668–1671
   Google Scholar
• Jalal DI, Rivard CJ, Johnson RJ, et al. Serum uric acid levels predict the development of albuminuria over 6 years in patients with type 1 diabetes: Findings from the coronary artery calcification in type 1 diabetes study. Nephrol Dial Transplant. 2010;25(6):1865–1869
   PubMed Web of Science ®Google Scholar
• Ficociello LH, Rosolowsky ET, Niewczas MA, et al. High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: Results of a 6-year follow-up. Diabetes Care. 2010;33(6):1337–1343
   PubMed Web of Science ®Google Scholar
• Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol. 2008;3(3):706–713
   PubMed Web of Science ®Google Scholar
• Chuengsamarn S, Rattanamongkolgul S, Jirawatnotai S. Association between serum uric acid level and microalbuminuria to chronic vascular complications in Thai patients with type 2 diabetes. J Diabetes Complications. 2014;28(2):124–129
   Google Scholar
• Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care. 2012;35(1):99–104
   PubMed Web of Science ®Google Scholar
• Kim WJ, Kim SS, Bae MJ, et al. High-normal serum uric acid predicts the development of chronic kidney disease in patients with type 2 diabetes mellitus and preserved kidney function. J Diabetes Complications. 2014;28(2):130–134
   Google Scholar
• Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Hypouricemia and hyperuricemia in type 2 diabetes: Two different phenotypes. Eur J Clin Invest. 2001;31(4):318–321
   Google Scholar
• Ito H, Abe M, Mifune M, et al. Hyperuricemia is independently associated with coronary heart disease and renal dysfunction in patients with type 2 diabetes mellitus. PLoS One. 2011;6(11):e27817
   Google Scholar
• Tanaka K, Hara S, Kushiyama A, et al. Risk of macrovascular disease stratified by stage of chronic kidney disease in type 2 diabetic patients: Critical level of the estimated glomerular filtration rate and the significance of hyperuricemia. Clin Exp Nephrol. 2011;15(3):391–397
   Google Scholar
• Momeni A, Shahidi S, Seirafian S, Taheri S, Kheiri S. Effect of allopurinol in decreasing proteinuria in type 2 diabetic patients. Iran J Kidney Dis. 2010;4(2):128–132
   PubMed Web of Science ®Google Scholar
• Miao Y, Ottenbros SA, Laverman GD, et al. Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011;58(1):2–7
   PubMed Web of Science ®Google Scholar
• Hunt SC, Stephenson SH, Hopkins PN, Williams RR. Predictors of an increased risk of future hypertension in Utah: A screening analysis. Hypertension. 1991;17(6Pt2):969–976
   Google Scholar
• Imazu M, Yamamoto H, Toyofuku M, et al. Hyperinsulinemia for the development of hypertension: Data from the Hawaii–Los Angeles–Hiroshima Study. Hypertens Res. 2001;24(5):531–536
   Google Scholar
• Alper AB Jr, Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: The Bogalusa Heart Study. Hypertension. 2005;45(1):34–38
   PubMed Web of Science ®Google Scholar
• Jossa F, Farinaro E, Panico S, et al. Serum uric acid and hypertension: The Olivetti Heart Study. J Hum Hypertens. 1994;8(9):677–681
   PubMed Web of Science ®Google Scholar
• Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension. 2007;49(2):298–303
   PubMed Web of Science ®Google Scholar
• Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck ML. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42(4):474–480
   Google Scholar
• Mellen PB, Bleyer AJ, Erlinger TP, et al. Serum uric acid predicts incident hypertension in a biethnic cohort: The atherosclerosis risk in communities study. Hypertension. 2006;48(6):1037–1042
   PubMed Web of Science ®Google Scholar
• Nagahama K, Inoue T, Iseki K, et al. Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res. 2004;27(11):835–841
   Google Scholar
• Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: The Normative Aging Study. Hypertension. 2006;48(6):1031–1036
   PubMed Web of Science ®Google Scholar
• Sundström J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45(1):28–33
   PubMed Web of Science ®Google Scholar
• Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, Okada K. Serum uric acid and the risk for hypertension and type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens. 2001;19(7):1209–1215
   PubMed Web of Science ®Google Scholar
• Syamala S, Li J, Shankar A. Association between serum uric acid and prehypertension among US adults. J Hypertens. 2007;25(8):1583–1589
   Web of Science ®Google Scholar
• Lee JE, Kim YG, Choi YH, Huh W, Kim DJ, Oh HY. Serum uric acid is associated with microalbuminuria in prehypertension. Hypertension. 2006;47(5):962–967
   Google Scholar
• Forman JP, Choi H, Curhan GC. Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol. 2007;18(1):287–292
   PubMed Web of Science ®Google Scholar
• Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension. 2003;42(3):247–252
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Adachi H, Hirai Y, et al. Serum uric acid is associated with the left ventricular mass index in males of a general population. Int Heart J. 2014;55(1):65–70
   Google Scholar
• Nitta K, Iimuro S, Imai E, et al. Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease. Clin Exp Nephrol. 2013;17(5):730–742
   Google Scholar
• Tsioufis C, Chatzis D, Vezali E, et al. The controversial role of serum uric acid in essential hypertension: Relationships with indices of target organ damage. J Hum Hypertens. 2005;19(3):211–217
   Google Scholar
• Boban M, Kocic G, Radenkovic S, et al. Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease. Ren Fail. 2014;36(4):613--618
   PubMed Web of Science ®Google Scholar
• Feig DI, Nakagawa T, Karumanchi SA, et al. Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int. 2004;66(1):281–287
   PubMed Web of Science ®Google Scholar
• Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821
   PubMed Web of Science ®Google Scholar
• Sheikhbahaei S, Fotouhi A, Hafezi-Nejad N, Nakhjavani M, Esteghamati A. Serum uric acid, the metabolic syndrome, and the risk of chronic kidney disease in patients with type 2 diabetes. Metab Syndr Relat Disord. 2014;12(2):102–109
   Google Scholar
• Sedaghat S, Hoorn EJ, van Rooij FJ, et al. Serum uric acid and chronic kidney disease: The role of hypertension. PLoS One. 2013;8(11):e76827
   Google Scholar
• Jalalzadeh M, Nurcheshmeh Z, Mohammadi R, Mousavinasab N, Ghadiani MH. The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia. J Res Med Sci. 2012;17(11):1039–1046
   Google Scholar
• Pai BH, Swarnalatha G, Ram R, Dakshinamurty KV. Allopurinol for prevention of progression of kidney disease with hyperuricemia. Indian J Nephrol. 2013;23(4):280–286
   Google Scholar
• Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH Trial). Circ J. 2013;77(8):2043–2049
   PubMed Web of Science ®Google Scholar
• Gois PH, Souza ER. Pharmacotherapy for hyperuricemia in hypertensive patients. Cochrane Database Syst Rev. 2013;1:CD008652
   PubMed Web of Science ®Google Scholar
• Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders – Facts and controversies. Biochem Med (Zagreb). 2012;22(1):63–75
   Google Scholar
• Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: A reaction to atherosclerosis? Atherosclerosis. 2000;148(1):131–139
   Web of Science ®Google Scholar
• Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. Proc Natl Acad Sci USA. 1981;78(11):6858–6862
   PubMed Web of Science ®Google Scholar
• Squadrito GL, Cueto R, Splenser AE, et al. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000;376(2):333–337
   PubMed Web of Science ®Google Scholar
• Kurra V, Eräranta A, Jolma P, et al. Hyperuricemia, oxidative stress, and carotid artery tone in experimental renal insufficiency. Am J Hypertens. 2009;22(9):964–970
   PubMed Web of Science ®Google Scholar
• Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta. 2008;392(1-2):1–7
   PubMed Web of Science ®Google Scholar
• Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003;41(6):1287–1293
   PubMed Web of Science ®Google Scholar
• Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553–3562
   PubMed Web of Science ®Google Scholar
• Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study. PLoS One. 2011;6(5):e19901
   PubMed Web of Science ®Google Scholar
• Ling Y, Li XM, Gao X. Cross-sectional association of serum C-reactive protein and uric acid with albuminuria in Chinese type 2 diabetic patients. Chin Med J (Engl). 2013;126(21):4023–4029
   Google Scholar
• Caravaca F, Martín MV, Barroso S, et al. Serum uric acid and C-reactive protein levels in patients with chronic kidney disease. Nefrologia. 2005;25(6):645–654
   PubMedGoogle Scholar
• Wang Y, Bao X. Effects of uric acid on endothelial dysfunction in early chronic kidney disease and its mechanisms. Eur J Med Res. 2013;18(1):26
   Google Scholar
• Dogan A, Yarlioglues M, Kaya MG, et al. Effect of long-term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press. 2011;20(3):182–187
   Web of Science ®Google Scholar
• Puddu P, Puddu GM, Cravero E, Vizioli L, Muscari A. Relationships among hyperuricemia, endothelial dysfunction and cardiovascular disease: Molecular mechanisms and clinical implications. J Cardiol. 2012;59(3):235–242
   PubMed Web of Science ®Google Scholar
• Waring WS, McKnight JA, Webb DJ, Maxwell SR. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia. 2007;50(12):2572–2579
   Google Scholar
• Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int. 2004;65(6):2380–2389
   PubMed Web of Science ®Google Scholar
• Liu WC, Hung CC, Chen SC, et al. Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol. 2012;7(4):541–548
   PubMed Web of Science ®Google Scholar
• Suliman ME, Johnson RJ, García-López E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 2006;48(5):761–771
   PubMed Web of Science ®Google Scholar
• Wen CP, David Cheng TY, Chan HT, et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis. 2010;56(2):273–288
   Google Scholar
• Navaneethan SD, Beddhu S. Associations of serum uric acid with cardiovascular events and mortality in moderate chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1260–1266
   Google Scholar
• Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol. 2012;36(4):324–331
   PubMed Web of Science ®Google Scholar
• Neri L, Rocca Rey LA, Lentine KL, et al. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: A historical cohort study based on laboratory and claims data from a national insurance provider. Am J Kidney Dis. 2011;58(3):398–408
   Google Scholar
• Chung W, Kim AJ, Ro H, Chang JH, Lee HH, Jung JY. Hyperuricemia is an independent risk factor for mortality only if chronic kidney disease is present. Am J Nephrol. 2013;37(5):452–461
   Google Scholar
• Terawaki H, Nakayama M, Miyazawa E, et al. Effect of allopurinol on cardiovascular incidence among hypertensive nephropathy patients: The Gonryo study. Clin Exp Nephrol. 2013;17(4):549–553
   Google Scholar
• Lee CT, Chua S, Hsu CY, et al. Biomarkers associated with vascular and valvular calcification in chronic hemodialysis patients. Dis Markers. 2013;34(4):229–235
   Google Scholar
• Antunovic T, Stefanovic A, Ratkovic M, et al. High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients. Int Urol Nephrol. 2013;45(4):1111–1119
   Google Scholar
• Lobo JC, Stockler-Pinto MB, da Nóbrega AC, Carraro-Eduardo JC, Mafra D. Is there association between uric acid and inflammation in hemodialysis patients? Ren Fail. 2013;35(3):361–366
   PubMed Web of Science ®Google Scholar
• Cohen SD, Kimmel PL, Neff R, Agodoa L, Abbott KC. Association of incident gout and mortality in dialysis patients. J Am Soc Nephrol. 2008;19(11):2204–2210
   Google Scholar
• Lee SM, Lee AL, Winters TJ, et al. Low serum uric acid level is a risk factor for death in incident hemodialysis patients. Am J Nephrol. 2009;29(2):79–85
   PubMed Web of Science ®Google Scholar
• Fourtunas C. Perceptions of gout (podagra) during the Byzantine era, with a special focus on a poem by Michael Psellus. J Nephrol. 2013;26(Suppl. 22):110–112
   Google Scholar
• Xia X, He F, Wu X, Peng F, Huang F, Yu X. Relationship between serum uric acid and all-cause and cardiovascular mortality in patients treated with peritoneal dialysis. Am J Kidney Dis. 2014;64(2):257–264
   PubMed Web of Science ®Google Scholar
• Feng S, Jiang L, Shi Y, et al. Uric acid levels and all-cause mortality in peritoneal dialysis patients. Kidney Blood Press Res. 2013;37(2--3):181–189
   Google Scholar
• Dong J, Han QF, Zhu TY, et al. The associations of uric acid, cardiovascular and all-cause mortality in peritoneal dialysispatients. PLoS One. 2014;9(1):e82342
   PubMed Web of Science ®Google Scholar
• Mazali FC, Mazzali M. Uric acid and transplantation. Semin Nephrol. 2011;31(5):466–471
   Google Scholar
• Einollahi B, Einollahi H, Nafar M, Rostami Z. Prevalence and risk factors of hyperuricemia among kidney transplant recipients. Indian J Nephrol. 2013;23(3):201–205
   Google Scholar
• Alpay N, Ozkok A, Caliskan Y, et al. Influence of conversion from calcineurin inhibitors to everolimus on fibrosis, inflammation, tubular damage and vascular function in renal transplant patients. Clin Exp Nephrol. 2014 [Epub ahead of print]. doi: 10.1007/s10157-014-0939-4
   Google Scholar
• Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Uric acid levels have no significant effect on renal function in adult renal transplant recipients: Evidence from the symphony study. Clin J Am Soc Nephrol. 2009;4(10):1655–1660
   PubMed Web of Science ®Google Scholar
• Gores PF, Fryd DS, Sutherland DE, Najarian JS, Simmons RL. Hyperuricemia after renal transplantation. Am J Surg. 1988;156(5):397–400
   PubMedGoogle Scholar
• Akgul A, Bilgic A, Ibis A, Ozdemir FN, Arat Z, Haberal M. Is uric acid a predictive factor for graft dysfunction in renal transplant recipients? Transplant Proc. 2007;39(4):1023–1026
   Google Scholar
• Akalin E, Ganeshan SV, Winston J, Muntner P. Hyperuricemia is associated with the development of the composite outcomes of new cardiovascular events and chronic allograft nephropathy. Transplantation. 2008;86(5):652–658
   PubMed Web of Science ®Google Scholar
• Gerhardt U, Grosse Hüttmann M, Hohage H. Influence of hyperglycemia and hyperuricemia on long-term transplant survival in kidney transplant recipients. Clin Transplant. 1999;13(5):375–379
   Google Scholar
• Armstrong KA, Johnson DW, Campbell SB, Isbel NM, Hawley CM. Does uric acid have a pathogenetic role in graft dysfunction and hypertension in renal transplant recipients? Transplantation. 2005;80(11):1565–1571
   PubMed Web of Science ®Google Scholar
• Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol. 2009;103(6):867–871
   PubMed Web of Science ®Google Scholar
• Min SI, Yun IJ, Kang JM, et al. Moderate-to-severe early-onset hyperuricaemia: A prognostic marker of long-term kidney transplant outcome. Nephrol Dial Transplant. 2009;24(8):2584–2590
   PubMed Web of Science ®Google Scholar
• Choi JY, Kwon OJ. The association between serum uric acid levels at 3 months after renal transplantation and the graft outcome in living donor renal transplantation. Transplant Proc. 2013;45(4):1548–1552
   Google Scholar
• Huang Y, Li YL, Huang H, Wang L, Yuan WM, Li J. Effects of hyperuricemia on renal function of renal transplant recipients: A systematic review and meta-analysis of cohort studies. PLoS One. 2012;7(6):e39457
   Google Scholar
• Weng SC, Shu KH, Tarng DC, et al. Uric acid is highly associated with kidney allograft survival in a time-varying analysis. Transplant Proc. 2014;46(2):505–510
   Google Scholar
• Hart A, Jackson S, Kasiske BL, et al. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: Post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. Transplantation. 2014;97(10):1066–1071
   Google Scholar
• Saglam F, Celik A, Sarioglu S, et al. Hyperuricemia influences chronic cyclosporine nephropathy. Transplant Proc. 2008;40(1):167–170
   Google Scholar
• Boratyńska M, Karbowska A, Klinger M. The effect of hyperuricemia on endothelial biomarkers and renal function in kidney allograft recipients. Transplant Proc. 2010;42(10):4074–4077
   Google Scholar